+44 20 8123 2220
info@marketpublishers.com

Global Insulin Biosimilar Market Size study, by Type (Fast-acting Insulin, Intermediate-acting Insulin, Long-acting Insulin), by Indication (Diabetes Type 1, Diabetes Type 2), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) and Regional Forecasts 2024-2032

https://marketpublishers.com/r/G00BED8D0B89EN.html
Date: August 2024
Pages: 200
Price: US$ 4,950.00 (Single User License)
ID: G00BED8D0B89EN

Abstracts

Global Insulin Biosimilar Market is projected to be valued at USD 2,832.39 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 6.2% during the forecast period, reaching USD 4867.14 million by 2032. Insulin biosimilars, which are biological products highly similar to approved insulin reference products, provide a more affordable treatment option without compromising efficacy. These biosimilars match the reference insulin in terms of safety, purity, and potency but may have minor differences in clinically inactive components. Primarily used to manage diabetes by regulating blood glucose levels, insulin biosimilars are employed in treating both Type 1 and Type 2 diabetes. By increasing market competition, biosimilars can reduce healthcare costs and enhance patient access to necessary insulin therapies.

The insulin biosimilar market is witnessing significant expansion due to the growing demand for cost-effective diabetes management solutions. The rising prevalence of diabetes globally acts as a catalyst for increasing insulin biosimilar sales. The market's growth is further propelled by the expiration of patents for several major insulin products, allowing for the development and commercialization of biosimilar versions. This surge in competition is driving down costs and improving accessibility for diabetic patients. The adoption of insulin biosimilars is particularly noteworthy in developing countries, where the prevalence of diabetes is rising, and there is a global push for improved access to affordable insulin therapy. Governments and healthcare

organizations are exploring biosimilars as a means to reduce treatment costs and enhance accessibility for patients.

Advancements in biotechnology and manufacturing processes are leading to the development of high-quality insulin biosimilars that closely resemble their reference products. This is increasing acceptance of biosimilars from healthcare professionals and patients alike, providing a positive outlook for the market. Strategic collaborations and partnerships between pharmaceutical companies and healthcare providers are becoming prevalent, aiming to streamline distribution channels and expand market reach for insulin biosimilars. Overall, the insulin biosimilar market is characterized by innovation, increased competition, and a focus on improving affordability and accessibility of diabetes treatment globally. Also, 0ngoing advancements in drug delivery systems are revitalizing the insulin biosimilar market. The development of advanced solutions like insulin jet injectors, implantable pumps, and smart injectors is making insulin delivery easier and more effective. While most companies aim for a presence in developed markets, there is a huge opportunity for insulin biosimilar companies to grow in emerging countries. To succeed in these markets, biosimilar players must adopt a strategic, long-term approach focused on delivering affordable products and enhancing access in areas with significant untapped demand. This entails pursuing consistent sales growth, albeit with smaller profit margins than in developed markets.

The global insulin biosimilar industry faces significant regulatory challenges that hinder its growth. Obtaining approval for biosimilar products involves demonstrating similarity to the reference product through extensive and costly clinical trials. Biologic products, often manufactured using genetically engineered systems, pose unique challenges due to the impossibility of creating identical copies. The proprietary nature of production processes for reference products and the inherent complexity of biological molecules amplifies the difficulty of biosimilar development.

The North America are likely to dominate the Insulin Biosimilars Market owing to the presence of major manufacturers, raising awareness, and rising product launches by major players in the region. The increasing patient pool with prediabetic and diabetes is driving the growth of the market in this region. Asia-Pacific is the fastest-growing regional market for insulin biosimilars. It has the world’s largest population and rapidly developing healthcare sector. The International Diabetes Federation estimated that more than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined.

Major market players included in this report are:

Eli Lilly and Company

Sanofi SA

BIOTON S.A.

WOCKHARDT
Julphar
Biocon Ltd.
Tonghua Dongbao
Polfa Tarchomin S.A.
Popular Pharmaceuticals Ltd
SEDICO Co.

The detailed segments and sub-segment of the market are explained below:
By Type:
• Fast-acting Insulin
• Intermediate-acting Insulin
• Long-acting Insulin
By Indication:
• Diabetes Type 1
• Diabetes Type 2
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
By Region:
• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

+44 20 8123 2220
info@marketpublishers.com

Contents

CHAPTER 9. COMPETITIVE INTELLIGENCE

+44 20 8123 2220
info@marketpublishers.com

CHAPTER 10. RESEARCH PROCESS

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

This list is not complete, final report does contain more than 100 tables. The list may be updated in the final deliverable.

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

This list is not complete, final report does contain more than 50 figures. The list may be updated in the final deliverable.

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Insulin Biosimilar Market Size study, by Type (Fast-acting Insulin, Intermediate-acting Insulin, Long-acting Insulin), by Indication (Diabetes Type 1, Diabetes Type 2), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) and Regional Forecasts 2024-2032

Product link: https://marketpublishers.com/r/G00BED8D0B89EN.html

Price: US$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G00BED8D0B89EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

+44 20 8123 2220
info@marketpublishers.com

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970